Urinary Tract Infection Therapeutic Market, By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and By Geogra

Urinary Tract Infection Therapeutic Market, By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs), By Indication (Complicated UTI, Uncomplicated UTI, and Other Indications), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2019, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

  • This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.
Detailed Segmentation:
  • Global Urinary Tract Infection Therapeutic Market By Drug:
  • Penicillin and Combinations
  • Quinolones
  • Cephalosporin
  • Azoles and Amphotericin B
  • Nitrofurans
  • Other Drugs
  • Global Urinary Tract Infection Therapeutic Market By Indication;
  • Complicated UTI
  • Uncomplicated UTI
  • Other Indications
  • Global Urinary Tract Infection Therapeutic Market By Geography:
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
  • Company Profiles:
  • Pfizer
  • Novartis AG
  • Cipla Inc.
  • Bayer AG
  • AstraZeneca
  • Shionogi & Co. Ltd.
  • GlaxoSmithKline PLC


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Urinary Tract Infection Therapeutic, By Drug
Market Urinary Tract Infection Therapeutic, By Indication
Market Urinary Tract Infection Therapeutic, By Geography
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
High prevalence of urinary tract infection across the globe
Adverse effects associated with the use of UTI medication
Increase in focus on the development of novel drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Urinary Tract Infection Therapeutic Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Urinary Tract Infection Therapeutic Market, By Drug, 2017-2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 – 2028
Segment Trends
Penicillin and Combinations
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Quinolones
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Cephalosporin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Azoles and Amphotericin B
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Nitrofurans
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Other Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
6. Global Urinary Tract Infection Therapeutic Market, By Indication, 2017-2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 – 2028
Segment Trends
Complicated UTI
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Uncomplicated UTI
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
Other Indications
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
7. Global Urinary Tract Infection Therapeutic Market, By Geography, 2017-2028, (US$ Mn)
Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 – 2028
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Middle East and Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
Rest of World
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
8. Competitive Landscape
Pfizer
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Cipla Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Bayer AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Shionogi & Co. Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Views
9. Section
Research Methodology
About us
*Browse 24 market data tables and 28 figures on "Urinary Tract Infection Therapeutic Market” – Global forecast to 2028.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings